MA30044B1 - Procede de traitement - Google Patents
Procede de traitementInfo
- Publication number
- MA30044B1 MA30044B1 MA31021A MA31021A MA30044B1 MA 30044 B1 MA30044 B1 MA 30044B1 MA 31021 A MA31021 A MA 31021A MA 31021 A MA31021 A MA 31021A MA 30044 B1 MA30044 B1 MA 30044B1
- Authority
- MA
- Morocco
- Prior art keywords
- ocular neovascular
- administration
- treating
- methods
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des procédés de traitement d'un trouble néovasculaire oculaire chez un mammifère par l'administration de dérivés de pyrimidine, de dérivés de benzodiazépinyle et des compositions pharmaceutiques en contenant. L'invention concerne également des procédés de traitement d'un trouble néovasculaire oculaire par l'administration de l'acide 5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]-2-pyrimidinyl]amino]-2-méthylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroéthyl)-2,3,4,5-tétrahydro-1H-2-benzazépine-4-acétique ou des sels et des solvates de celui-ci. L'invention concerne en outre des thérapies de combinaison pour le traitement de troubles néovasculaires oculaires.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74047805P | 2005-11-29 | 2005-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30044B1 true MA30044B1 (fr) | 2008-12-01 |
Family
ID=38037895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31021A MA30044B1 (fr) | 2005-11-29 | 2008-06-11 | Procede de traitement |
Country Status (28)
Country | Link |
---|---|
US (1) | US20080293691A1 (fr) |
EP (2) | EP1968594B1 (fr) |
JP (1) | JP5180834B2 (fr) |
KR (1) | KR20080071188A (fr) |
CN (1) | CN101370505B (fr) |
AT (1) | ATE482708T1 (fr) |
AU (2) | AU2006320535B2 (fr) |
BR (1) | BRPI0619057A2 (fr) |
CA (1) | CA2631173A1 (fr) |
CR (1) | CR10010A (fr) |
CY (1) | CY1111047T1 (fr) |
DE (1) | DE602006017261D1 (fr) |
DK (1) | DK1968594T3 (fr) |
EA (1) | EA016227B1 (fr) |
ES (2) | ES2392030T3 (fr) |
HK (1) | HK1121386A1 (fr) |
HR (1) | HRP20100559T1 (fr) |
IL (1) | IL191027A0 (fr) |
MA (1) | MA30044B1 (fr) |
MX (1) | MX2008006379A (fr) |
MY (1) | MY144750A (fr) |
NO (1) | NO20081963L (fr) |
NZ (1) | NZ568075A (fr) |
PL (1) | PL1968594T3 (fr) |
PT (1) | PT1968594E (fr) |
SI (1) | SI1968594T1 (fr) |
UA (1) | UA94427C2 (fr) |
WO (1) | WO2007064752A2 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3069576A1 (fr) * | 2008-01-09 | 2009-07-16 | The Schepens Eye Research Institute, Inc. | Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires |
US8076475B2 (en) * | 2008-03-06 | 2011-12-13 | Glaxosmithkline Llc | Process |
SG173167A1 (en) | 2009-01-29 | 2011-08-29 | Forsight Labs Llc | Posterior segment drug delivery |
MX2012000706A (es) * | 2009-07-16 | 2012-06-01 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento. |
EP2490536A4 (fr) * | 2009-10-23 | 2013-04-17 | Glaxo Wellcome Mfg Pte Ltd | Compositions et procédés |
WO2011058179A1 (fr) | 2009-11-16 | 2011-05-19 | Ratiopharm Gmbh | 5-(4-(n-(2,3-diméthyl-2h-indazol-6-yl)-n-méthylamino)pyrimidin-2-ylamino)-2-méthylbenzènesulfonamide |
WO2011069053A1 (fr) | 2009-12-04 | 2011-06-09 | Teva Pharmaceutical Industries Ltd. | Procede de preparation de pazopanip hcl et formes cristallines de pazopanib hcl |
TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
EP2600930B1 (fr) | 2010-08-05 | 2021-02-17 | ForSight Vision4, Inc. | Appareil d'injection pour l'administration de médicaments |
CA2890554A1 (fr) * | 2010-10-07 | 2012-04-12 | Aerpio Therapeutics Inc. | Compositions et methodes de traitement d'un oedeme oculaire, de neovascularisation et de maladies associees |
WO2012068549A2 (fr) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Formulations d'agents thérapeutiques pour des dispositifs implantés |
US20140018402A1 (en) * | 2011-03-30 | 2014-01-16 | Catholic University Industry Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating macular degeneration |
WO2013000917A1 (fr) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Composition pharmaceutique topique ophtalmologique contenant du régorafénib |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
CA2848385C (fr) | 2011-09-16 | 2021-10-26 | Forsight Vision4, Inc. | Methodes et appareil d'echange d'un fluide d'un dispositif implantable |
US9278099B2 (en) * | 2011-10-31 | 2016-03-08 | Novartis Ag | Pazopanib formulation |
RU2014126070A (ru) | 2011-12-01 | 2016-01-27 | Глэксо Груп Лимитед | Способы лечения и предотвращения глазных заболеваний |
CN102657655B (zh) * | 2012-05-17 | 2014-05-21 | 大连理工大学 | 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用 |
WO2013188283A1 (fr) | 2012-06-12 | 2013-12-19 | Bayer Healthcare Llc | Composition pharmaceutique ophtalmique topique contenant du sunitinib |
US9802923B2 (en) | 2012-12-17 | 2017-10-31 | Sun Pharmaceutical Industries Limited | Process for the preparation of pazopanib or salts thereof |
WO2014097152A1 (fr) | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Procédé de préparation du pazopanib ou de ses sels |
UY35183A (es) | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
WO2015068175A2 (fr) | 2013-11-05 | 2015-05-14 | Laurus Labs Private Limited | Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP2017524034A (ja) | 2014-08-08 | 2017-08-24 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法 |
KR20170043655A (ko) * | 2014-09-09 | 2017-04-21 | 아르투로 솔리스 헤레라 | 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 |
AU2015346450B2 (en) | 2014-11-10 | 2020-01-30 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
US11306140B2 (en) | 2016-01-07 | 2022-04-19 | The Schepens Eye Research Institute, Inc. | Therapeutics for ocular immunoinflammatory diseases |
BR112018070383A2 (pt) | 2016-04-05 | 2019-02-05 | Forsight Vision4 Inc | dispositivos para aplicação de fármaco oculares implantáveis |
CN106565688B (zh) * | 2016-11-11 | 2018-08-31 | 重庆医科大学 | 帕唑帕尼二聚体及其制备方法和用途 |
EP3694890A4 (fr) | 2017-10-12 | 2021-11-03 | Immunowake Inc. | Protéine de fusion à chaîne légère d'anticorps vegfr |
CA3082891A1 (fr) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Appareil d'echange de fluide pour systeme d'administration a port extensible et methodes d'utilisation |
CN110878089A (zh) * | 2018-09-05 | 2020-03-13 | 江苏豪森药业集团有限公司 | 一种盐酸帕唑帕尼的制备方法 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US5322691A (en) | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
DE3905050A1 (de) | 1989-02-18 | 1990-08-30 | Lohmann Therapie Syst Lts | Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii) |
US4946450A (en) | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5290892A (en) | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
FR2690846B1 (fr) | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | Forme galenique pour administration oculaire et procede de preparation. |
WO1995003009A1 (fr) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Methode de traitement de la degenerescence maculaire |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
US5710165A (en) | 1994-07-06 | 1998-01-20 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
ES2191719T3 (es) | 1994-11-10 | 2003-09-16 | Univ Kentucky Res Found | Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo. |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5824073A (en) | 1996-03-18 | 1998-10-20 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
US5743274A (en) | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
US20030125317A1 (en) * | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
WO1999007418A2 (fr) | 1997-08-11 | 1999-02-18 | Allergan Sales, Inc. | Implant bio-erodable sterile a biocompatibilite accrue et methode |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6146366A (en) | 1998-11-03 | 2000-11-14 | Ras Holding Corp | Device for the treatment of macular degeneration and other eye disorders |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6660960B2 (en) | 1999-12-28 | 2003-12-09 | K. K. Endo Seisakusho | Method for manufacturing golf club |
US6719750B2 (en) | 2000-08-30 | 2004-04-13 | The Johns Hopkins University | Devices for intraocular drug delivery |
NZ526542A (en) * | 2000-12-21 | 2005-01-28 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
US7592016B2 (en) | 2001-06-28 | 2009-09-22 | Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
US7195774B2 (en) | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
AU2003231730A1 (en) * | 2002-05-03 | 2003-11-17 | Alcon, Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
MXPA04012860A (es) * | 2002-06-17 | 2005-09-20 | Smithkline Beecham Corp | Proceso quimico. |
US20070208023A1 (en) * | 2004-04-16 | 2007-09-06 | Smithkline Beecham Corporation | Cancer Treatment Method |
NZ596663A (en) * | 2004-10-21 | 2013-07-26 | Genentech Inc | Use of vegf antagonists in intraocular neovascular disease treatment |
WO2006117666A2 (fr) * | 2005-04-29 | 2006-11-09 | Pfizer Inc. | Formes posologques, compositions pharmaceutiques et methodes d'administration sous la capsule de tenon |
-
2006
- 2006-11-29 AU AU2006320535A patent/AU2006320535B2/en not_active Ceased
- 2006-11-29 DE DE602006017261T patent/DE602006017261D1/de active Active
- 2006-11-29 EP EP06838635A patent/EP1968594B1/fr active Active
- 2006-11-29 PL PL06838635T patent/PL1968594T3/pl unknown
- 2006-11-29 US US12/094,672 patent/US20080293691A1/en not_active Abandoned
- 2006-11-29 BR BRPI0619057-0A patent/BRPI0619057A2/pt not_active IP Right Cessation
- 2006-11-29 EA EA200801168A patent/EA016227B1/ru not_active IP Right Cessation
- 2006-11-29 MX MX2008006379A patent/MX2008006379A/es active IP Right Grant
- 2006-11-29 CN CN2006800445634A patent/CN101370505B/zh not_active Expired - Fee Related
- 2006-11-29 ES ES10170798T patent/ES2392030T3/es active Active
- 2006-11-29 UA UAA200805311A patent/UA94427C2/ru unknown
- 2006-11-29 DK DK06838635.8T patent/DK1968594T3/da active
- 2006-11-29 SI SI200630844T patent/SI1968594T1/sl unknown
- 2006-11-29 JP JP2008542486A patent/JP5180834B2/ja not_active Expired - Fee Related
- 2006-11-29 AT AT06838635T patent/ATE482708T1/de active
- 2006-11-29 KR KR1020087015035A patent/KR20080071188A/ko not_active Application Discontinuation
- 2006-11-29 WO PCT/US2006/045776 patent/WO2007064752A2/fr active Application Filing
- 2006-11-29 EP EP10170798A patent/EP2329821B1/fr active Active
- 2006-11-29 NZ NZ568075A patent/NZ568075A/en not_active IP Right Cessation
- 2006-11-29 ES ES06838635T patent/ES2350858T3/es active Active
- 2006-11-29 CA CA002631173A patent/CA2631173A1/fr not_active Abandoned
- 2006-11-29 PT PT06838635T patent/PT1968594E/pt unknown
-
2008
- 2008-04-25 NO NO20081963A patent/NO20081963L/no not_active Application Discontinuation
- 2008-04-27 IL IL191027A patent/IL191027A0/en unknown
- 2008-05-22 CR CR10010A patent/CR10010A/es not_active Application Discontinuation
- 2008-05-27 MY MYPI20081798A patent/MY144750A/en unknown
- 2008-06-11 MA MA31021A patent/MA30044B1/fr unknown
-
2009
- 2009-02-13 HK HK09101370.9A patent/HK1121386A1/xx not_active IP Right Cessation
-
2010
- 2010-10-13 HR HR20100559T patent/HRP20100559T1/hr unknown
- 2010-12-06 AU AU2010249187A patent/AU2010249187A1/en not_active Abandoned
- 2010-12-21 CY CY20101101174T patent/CY1111047T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30044B1 (fr) | Procede de traitement | |
BRPI0414435A (pt) | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios | |
BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
EA200400476A1 (ru) | Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция | |
ATE500831T1 (de) | Krebsbehandlungsverfahren | |
TW200716139A (en) | Methods and compositions for managing psychotic disorders | |
MA29795B1 (fr) | Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete | |
NO20040511L (no) | Aminoisoxazolderivater som kinaseinhibitorer | |
NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
DK2201840T3 (da) | Hæmmere af Brutons tyrosinkinase | |
IL186566A0 (en) | Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels | |
NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
NO20052059L (no) | Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta. | |
NO20071704L (no) | Prostaglandinderivater for behandling av gastrointestinal forstyrrelse | |
BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca | |
TW200730507A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
DE60327634D1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
MY128882A (en) | Novel use of substituted aminomethyl chromans | |
BR0307427A (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica, método para tratar de um paciente humano ou animal que esteja sofrendo de uma condição que seja medida por cox-2, e, uso de uma composição farmacêutica | |
JP2002371012A (ja) | プリオン病の薬のつくりかた |